AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the Listing Regulations, please find enclosed copies of financial results of the Company for the quarter ended 30th June 2022 published in following newspapers on 29th July 2022: 1. Mumbai edition of Economic Times and 2. Mumbai edition of Maharashtra Times; This is for your information and record. AJANTA PHARMA LTD. - 532331 - Audio Recording Of Earnings Call Conducted On 28Th July 2022
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 28th July 2022 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link: http://www.ajantapharma.com/AdminData/Results/EarningsCallAudioQ1(Apr-Jun)2022-23.mp3 Written transcript of the same will be submitted in due course. This is for your information and records please. Q1FY23 Quarterly Result Announced for Ajanta Pharma Ltd.
Pharmaceuticals firm Ajanta Pharma Announced Q1FY23 Result : Revenue from operations at Rs. 951 cr. against Rs. 748 cr.; up 27%. EBITDA at Rs. 222 cr. against Rs. 220 cr.; EBITDA at 23% of Revenue from Operations. Profit after tax at Rs. 175 cr. against Rs. 174 cr.; PAT at 18% of Revenue from Operations. Result PDF AJANTA PHARMA LTD. - 532331 - Results For Quarter Ended 30Th June 2022
At the Board meeting held today, the Board has inter-alia approved and taken on record Unaudited Financial results for the quarter ended 30th June 2022. Pursuant to Regulation 33 of SEBI LODR Regulations, 2015, we enclose herewith the following: i. Press Release being issued on the Results for the quarter ended 30th June 2022; ii. Unaudited Consolidated Financial Results for the quarter ended 30th June 2022; iii. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Consolidated Financial Results for the quarter ended 30th June 2022; iv. Unaudited Standalone Financial Results for the quarter ended 30th June 2022; v. Limited Review Report from Auditors M/s B S R & Co. LLP on the unaudited Standalone Financial Results for the quarter ended 30th June 2022; vi. Investors' presentation. Kindly note that the meeting of the Board of Directors commenced at 2.00 p.m. and concluded at 3.50 p.m. and take the above on your records. AJANTA PHARMA LTD. - 532331 - Board Meeting Outcome for Outcome Of Board Meeting
Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following: i. Press Release being issued on the Results for the quarter ended 30th June 2022; ii. Unaudited Consolidated Financial Results for the quarter ended 30th June 2022; iii. Limited Review Report from Auditors, M/s B S R & Co. LLP, on the unaudited Consolidated Financial Results for the quarter ended 30th June 2022; iv. Unaudited Standalone Financial Results for the quarter ended 30th June 2022; v. Limited Review Report from Auditors, M/s B S R & Co. LLP, on the unaudited Standalone Financial Results for the quarter ended 30th June 2022; vi. Investors' presentation. Kindly note that the meeting of the Board of Directors commenced at 2.00 p.m. and concluded at 3.50 p.m. and take the above on your records. AJANTA PHARMA LTD. - 532331 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Information on loss of shares AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith the schedule of Earnings Conference Call to be held on 28th July 2022, post Board meeting. This is for your information and records please. AJANTA PHARMA LTD. - 532331 - Board Meeting Intimation for Considering And Approving Unaudited Consolidated And Standalone Financial Results
AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2022 ,inter alia, to consider and approve Unaudited consolidated and standalone financial results of the Company for the first quarter ended 30th June 2022. AJANTA PHARMA LTD. - 532331 - Updates on Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Updates on Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 12, 2022 for Ravi P Agrawal, trustee Ravi Agrawal Trust AJANTA PHARMA LTD. - 532331 - Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- Gaurang ShahDesignation :- Company Secretary and Compliance Officer